Citalopram
As of the edition of 20 October 2026, Citalopram is a small molecule: marketed, first approved in 1990 (CH); acts on SLC6A4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Celexa
- First approved
- 14 December 1990 (CH)
- Approvals on record
- 15 in 5 regions
- Holder of the most recent approval
- Almatica Pharma; 8 holders in all
- Registered trials
- 118, 12 stopped early
- Disease areas
- Mental health; Nervous system; Digestive system; Heart and blood vessels; Chemically induced; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Citalopram.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | P31645 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 42 | 25 | 3 | 4 |
| Phase 1 | 18 | 18 | 0 | 0 |
| Phase 2 | 19 | 14 | 0 | 4 |
| Phase 3 | 16 | 13 | 0 | 2 |
| Phase 4 | 23 | 14 | 0 | 2 |
| All trials | 118 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Actavis | Applicant and Lead sponsor of trials | 1998 to now |
| Lundbeck | Applicant | 1999 to now |
| Bausch Health | Later holder | 2005 to now |
| Almatica Pharma | Later holder | 2022 to now |
| AbbVie | Acquired holder | 2023 to now |